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ABSTRACT 
Objective: To examine whether cytokines shown to suppress osteoblasts, Dickkopf-1 (DKK1) and hepatocyte growth 
factor (HGF), are associated with periarticular bone loss in rheumatoid arthritis (RA). Methods: RA patients with short 
disease duration were prospectively followed and hand bone mineral density was assessed by digital X-ray radiogram- 
metry (DXR) at baseline and after 1, 2 and 5 years. Plasma samples collected at baseline from 136 of the included pa- 
tients were analyzed for HGF and DKK1. Group comparisons, correlation analyses and multivariate analyses were per- 
formed to evaluate the relationship between baseline cytokine levels and DXR-BMD. Results: Patients with hand bone 
loss after 1 year had significantly higher baseline plasma levels of DKK1 than patients without bone loss. Patients with 
periarticular bone loss after 2 and 5 years had significantly higher baseline plasma levels of HGF. Baseline DKK1 but 
not HGF levels were independently associated with periarticular bone loss after 1 year. Conclusion: High serum levels 
of DKK1 are weakly but independently associated with periarticular bone loss in RA. The importance of DKK1 and 
HGF for loss of periarticular bone needs to be defined in future studies. 
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1. Introduction 
Bone loss presents as focal joint erosions, periarticular 
bone loss and generalized osteoporosis in rheumatoid ar- 
thritis (RA). Periarticular bone loss occurs within the 
bone adjacent to inflamed joints and has been shown to 
precede and predict development of erosions [1]. Inflam- 
matory cytokines involved in osteoclast differentiation  
and activation is thought to be the dominant mechanism 
behind the development of both erosions and periarticu- 
lar bone loss [2]. Recent data, however, suggest that oste- 
oblasts and their precursors are also influenced by RA 
inflammation, hypothesizing that lack of bone repair con- 
tribute to the development of erosions [3-5].  
Osteoblast dysfunction in relation to the development 
of periarticular bone loss has not been thoroughly studied. 
Central signaling pathways in osteoblast differentiation are 
the wingless (Wnt)-signaling pathway and the bone mor- 
phogenetic protein (BMP) pathway. Inhibitors of these 
pathways, Dickkopf-1 (DKK1) and hepatocyte growth 
factor (HGF), respectively, inhibit osteoblast differentia- 
tion and are associated with bone destruction in RA and 
multiple myeloma [4-8]. 
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radiogrammetry (DXR) [1], whereas presence of focal 
erosions is commonly evaluated by scoring radiographs 
according to the Sharp Heijde method [9]. In a previous 
study on the same cohort we found that plasma level of 
HGF, but not DKK1, was an independent predictor of ra- 
diographic damage of joints both at short- and long-term 
follow-up [10]. In the present study we wanted to inves- 
tigate if DKK1 and HGF were associated with periarti- 
cular hand bone loss assessed by DXR in RA. 
2. Materials and Methods 
2.1. Patients 
The patients were recruited from the European Research 
on Incapacitating Disease and Social Support study 
(EURIDISS). The study enrolled 238 patients with RA of 
less than four years disease duration in 1992 [1,11,12]. 
The study was performed in compliance with Helsinki 
declaration and approved by regional ethics committee 
(REK Sør-Øst, number 2009/1770a). All patients had gi- 
ven informed consent. Patients were assessed at baseline 
and after 1, 2, 5 and 10 years. In total, 136 patients had 
both radiographs available for the 5-year follow-up and 
plasma samples stored at baseline. There were no signi- 
ficant differences between baseline characteristics of RA 
patients with or without available data (Table 1). 
2.2. Plasma Samples and Laboratory Analyses 
Samples were obtained at enrolment and stored at −70˚C 
with no freezing and thawing. Levels of HGF, DKK1, 
Anti-CCP, rheumatoid factor (RF), C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR) were 
measured as previously described [10,13]. 
 
Table 1. Baseline characteristics of the study population 
and the excluded patients in the cohort. 
 Included patients N = 136 
Excluded patients 
N = 102 
Female % 76 71 
Disease duration  
mean ± SD years 2.2 ± 1.2 2.4 ± 1.1 
Age mean ± SD years 51.3 ± 12.1 52.8 ± 14.2 
Anti CCP positive, % 62 59 
RF IgM positive, % 48 48 
Steroid treatment, % 26 29 
DMARD treatment, % 54 49 
CRP, mean ± SD mg/L 12 ± 17 13 ± 16 
ESR, mean ±  
SD mm/hour 26.2 ± 20.8 25.5 ± 18.3 
Baseline vdHeijde Sharp  
score, median (IQR) 2 (8) 3 (10) (n = 26) 
2.3. Radiographs and DXR-BMD 
Conventional hand radiographs were analyzed with the 
DXR Pronosco X-posure system, V. 2.0 (Sectra, Linköp- 
ing, Sweden). DXR-BMD was calculated based on hand 
radiographs taken at baseline and after 1, 2 and 5 years of 
observation. Least significant change (LSC) was used as 
a cut-off to define loss in DXR-BMD exceeding the mea- 
surement error on the individual level and calculated as 
previously reported [1]. 
2.4. Statistics 
Statistical analyses were performed using SPSS19 (IBM- 
SPSS, Chicago, Illinois, USA).  
Variables were selected for multivariate analyses bas- 
ed on previous studies on the EURIDISS material and 
known prognostic factors for radiographic progression in 
RA: Baseline DXR BMD, gender, CRP, ESR, age at in- 
clusion, disease duration, anti-CCP positivity, RF IgM 
positivity, current DMARD and corticosteroid dose. The 
factors with a p-value < 0.15 in univariate analyses were 
included in multivariate analyses. 
3. Results 
3.1. Radiographic Results 
Mean (SD) DXR BMD was 0.547(0.088) at baseline, 
0.532(0.092) at one year, 0.522(0.092) at two years, and 
0.508(0.098) at 5 years’ follow-up. The proportion of pa- 
tients with DXR hand bone loss exceeding LSC was 67% 
at 1 year, 79% at 2 years and 89% after 5 years. 
3.2. Associations between HGF and DKK1  
Levels and Baseline Characteristics 
The median baseline levels of HGF and DKK1 were 723 
pg/mL (interquartile range (IQR) 255) and 1575 pg/mL 
(IQR 3230), respectively. 
HGF levels at baseline were positively correlated to 
age (rho 0.50, p < 0.001) and markers of inflammation 
(CRP, rho 0.21, p < 0.05, ESR, rho 0.39, p < 0.001) 
whereas DKK1 levels did not correlate to these parame- 
ters. There was a slightly higher median HGF level in the 
anti-CCP positive group (742.0 pg/mL, IQR 282.5, p < 
0.05) compared with the anti-CCP negative group (668.5 
pg/mL, IQR 240) but no difference in the baseline DKK- 
1 level comparing these two groups. 
3.3. Higher Levels of DKK1 in Patients  
Developing Periarticular Osteoporosis 
DKK1 plasma levels at baseline were significantly higher 
(2010 pg/mL, IQR 3086) in patients developing periarti- 
cular bone loss after 1 year compared with patients with- 
out periarticular bone loss (1332.2 pg/mL, IQR 2094, p = 
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0.03), but this difference was not present at 2- and 5- 
years follow up (2104.9 pg/mL, IQR 3062.5 vs 1790.4 
pg/mL, IQR 2782, p = 0.4 and 2087.1 pg/mL, IQR 
3084.9 vs 1105.8 pg/mL, IQR 1885.9, p = 0.13, respec- 
tively). 
3.4. Higher Levels of HGF in Patients  
Developing Periarticular Osteoporosis 
Baseline HGF levels were borderline significantly higher 
in the group of patients who developed periarticular bone 
loss compared with patients who did not after one-year 
follow up (769 pg/mL, IQR 277 vs. 653 pg/mL, IQR 229, 
p = 0.056) and significantly higher in the group of pa- 
tients who developed periarticular bone loss after 2 years 
(752 pg/mL, IQR 284) and 5 years (737 pg/mL, IQR 271) 
compared with patients who did not (676 pg/mL, IQR 
199 and 622 pg/mL, IQR 303, p = 0.038, p = 0.045, re- 
spectively). 
3.5. Associations between Cytokine Levels and  
Prospective Bone Loss 
Levels of HGF were associated with percentage bone 
loss at 1, 2 and 5 years (p = 0.001, p = 0.001, p = 0.005). 
Levels of DKK1 were significantly associated with per- 
centage bone loss at 1-year observation (p = 0.013), but 
not after 2 years (p = 0.094) or 5 (p = 0.714) (Table 2). 
In multivariate regression analyses levels of DKK1 
were found to be significantly associated with percentage 
bone loss at 1-year observation as were also CRP, ESR, 
and anti-CCP (Table 3). Baseline plasma levels of 
DKK1 were not associated with percentage bone loss 
after 2 and 5 years (β: 0.105, p = 0.193, β: 0.01, p = 
0.907, respectively). 
HGF was not associated with percentage bone loss in 
multivariate regression models at any time point (1 year:  
 
Table 2. Associations with baseline plasma levels of cyto- 
kines and percentage bone loss. 
Standardized β R2 p-valueBaseline cytokine 
levels 
Percentage bone loss after 1 year observation 
DKK1 pg/mL 0.214 0.046 0.013 
HGF pg/mL 0.285 0.081 0.001 
 Percentage bone loss after 2 years observation
DKK1 pg/mL 0.148 0.022 0.094 
HGF pg/mL 0.298 0.089 0.001 
 Percentage bone loss after 5 years observation
DKK1 pg/mL 0.034 0.001 0.714 
HGF pg/mL 0.255 0.065 0.005 
Table 3. Baseline predictors of percentage bone loss after 1- 
year observation. 
 β p R² combined  regression model 
CRP −0.280 0.008 
ESR 0.597 <0.001 
Anti-CCP positive 0.232 0.008 
DKK1 0.178 0.022 
0.355 
 
β: 0.092, p = 0.319, 2 year. β: 0.080, p = 0.405, 5 year. β: 
0.083, p = 0.400). 
4. Discussion 
The main finding in this study is that high plasma levels 
of DKK1 at baseline are independently associated with 
short-term loss of periarticular bone-mass assessed by 
DXR-BMD. These findings support that, as for the de- 
velopment of focal erosions, osteoblast suppression may 
play a role in the development of periarticular bone loss. 
In a previous study from the same cohort we found 
that levels of DKK1 at baseline were not associated with 
development of focal erosions assessed by Sharp Heijde 
score [10], while we here found DKK1 to weakly but 
independently predict periarticular bone loss at 1-year 
follow up. Even though such a conclusion cannot be 
made based on the present study, this raises the hypothe- 
sis of an even more important role for DKK1 in devel- 
opment of periarticular bone loss as compared to devel- 
opment of erosions. 
Levels of HGF, on the other hand, was shown to be an 
independent predictor of radiographic damage of joints 
both at short- and long-term follow-up [10], but was not 
associated with periarticular bone loss in adjusted analy- 
ses at any time point. Although we and others have shown 
that HGF inhibits osteoblast differentiation [6,7] it seems 
clear that the effect of HGF on osteoblast differentiation 
is dependent on the concentration of the cytokine, and that 
HGF at low concentrations in fact may promote rather 
than inhibit osteoblastogenesis [14]. Plasma levels of HGF 
correlate to levels of HGF in synovial fluid, and levels of 
HGF are higher in synovial fluid than in serum obtained 
simultaneously from the same individuals [15,16]. Hence, 
HGF at high concentrations in the joints are more likely 
to act negatively on osteoblasts than HGF at the lower 
concentrations found in circulation. On the other hand, 
lack of an independent association of HGF with periarti- 
cular bone loss might also be due to confounding or me- 
thodological issues.  
There are several important limitations to this study. 
First of all, the observed associations are rather weak and 
need to be confirmed in future studies. It is not possible 
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to draw conclusions regarding mechanisms for patho- 
physiologic processes based on plasma levels of cyto- 
kines. 
Periarticular bone loss was determined by examination 
of radiographs of the hands only, while cytokine levels 
measured in the circulation probably reflect the degree of 
inflammation and destruction in several joints. Preanaly- 
sis sources of variation (different treatment regimens, 
diurnal variation, comorbidity) as well as possible effects 
of sampling and storage can affect plasma levels of cyto- 
kines and must be taken into account in the interpretation 
of the data. Another important limitation is the small group 
of patients (n = 13) that were classified as not having a 
significant loss in DXR BMD at 5 years observation. 
Thus the group is probably too small to reveal any asso- 
ciation between the measured cytokines and hand bone 
loss in a long-term perspective. 
5. Conclusion 
Our data suggest an independent association of plasma 
levels of DKK1 and loss of periarticular bone in RA. The 
relative importance of DKK1 and HGF in terms of loss 
of periarticular bone compared with development of ero- 
sions needs to be explored in future studies. 
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